Traumatic birth ranged from 7% to 69% across 31 countries in one survey
The INTERSECT study asked 11,302 women 6 to 12 weeks postpartum about birth trauma. The spread between countries is far wider than the average, and that is the finding.
A psychedelic could win FDA approval within months. None ever has.
The agency compressed review of three psychedelic therapies from a year to weeks. A first approval decision is plausible by early 2027.
At-home ketamine's entire evidence base came from the companies selling it
A systematic review screened 3,857 records and found three eligible studies, every one produced by a US commercial provider and every one at critical risk of bias.
In veterans, psilocybin's anxiety relief tracked entirely with depression improvement
Anxiety, quality of life and PTSD symptoms all improved after a single dose in this 15-person trial. Once researchers accounted for depression improvement, those effects mostly disappeared.
A methylone drug eased PTSD in phase 2, without MDMA trials' long therapy sessions
TSND-201 improved PTSD severity, disability, and depression scores over placebo in 65 participants — delivered as an oral dose with monitoring but no formal psychotherapy alongside it.
After a lastingly distressing psychedelic experience, nearly a third met PTSD criteria
A survey of 243 people reporting persistent difficulty after a psychedelic trip found that how they responded in the moment, avoiding versus accepting, predicted whether trauma symptoms followed.
Insomnia flagged a disputed parasomnia in Ukrainian combatants
In 99 men hospitalised for stress-related disorders, roughly four in five met probable criteria for trauma-associated sleep disorder — a condition that is not yet a recognised diagnosis.